Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2022 Earnings Conference Call October 27, 2022 5:00 PM ET Company Participants Edward Chung - VP, IR Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Schwartz - Chairman, CEO & President Dara Wright - EVP & President, Clinical Diagnostics Group Simon May - EVP & President, the Life Science Group Conference Call Participants Patrick Donnelly - Citigroup Brandon Couillard - Jefferies Daniel Leonard - Crédit Suisse Jack Meehan - Nephron Research Operator Good even ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-138 ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2022 Earnings Conference Call July 28, 2022 6:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Simon May - President of Life Science Group Dara Wright - President of Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Operator Good afternoon. Thank you for atte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2022 Earnings Conference Call April 28, 2022 6:00 PM ET Company Participants Ed Chung - Head of Investor Relations Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Simon May - President of Life Science Group Norman Schwartz - Chief Executive Officer Dara Wright - President of Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Citi Brandon Couillard - Jefferies Jack ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...

Financial Data and Key Metrics Changes - Net sales for Q4 2021 were $732.8 million, a 7.2% decrease from $789.8 million in Q4 2020 [15] - On a currency-neutral basis, sales decreased 6.9%, primarily due to lower COVID-related sales and a $32 million litigation award included in Q4 2020 [16][36] - Reported gross margin for Q4 2021 was 54.7%, down from 58.3% in Q4 2020, mainly due to the prior year's settlement payment and increased costs [24] - Reported net loss for Q4 was $1.574 billion, with a diluted loss per share of $52.59, largely influenced by changes in the valuation of Sartorius Holdings [29] Business Line Data and Key Metrics Changes - Life Science group sales in Q4 2021 were $326.6 million, a 23.8% decline from $428.5 million in Q4 2020; however, excluding COVID-related sales, core revenue grew 7.9% [20] - Clinical Diagnostics group sales in Q4 were $404.9 million, a 12.6% increase from $359.6 million in Q4 2020, with core revenue growth of 12.1% excluding COVID-related sales [22] Market Data and Key Metrics Changes - Currency-neutral year-over-year core revenue growth was experienced across all three regions, while COVID-related sales declined globally [19] - The Diagnostics group saw mid-single-digit growth in the Americas and double-digit growth in Europe and Asia [23] Company Strategy and Development Direction - The company is focusing on three key areas: employee safety, maintaining manufacturing operations, and advancing core strategies [9] - The company anticipates ongoing supply chain constraints into Q2 2022 but expects recovery and growth acceleration in the second half of the year [12][48] - The Life Science group is expected to see year-over-year currency-neutral revenue growth between flat and 1.5%, with significant declines in COVID-related sales [50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of core product demand, which has returned to near-normal levels despite ongoing supply chain challenges [14] - The company expects lower year-over-year growth in the first half of 2022, with higher growth anticipated in the latter half [47][49] Other Important Information - Total cash and short-term investments at the end of 2021 were $875 million, down from $997 million at the end of 2020 [42] - The company plans to hold an in-person Investor Day on February 25 at the New York Stock Exchange [52] Q&A Session Summary Question: Outlook on top line growth - Management indicated that the guidance reflects execution of core strategies, with growth driven by biopharma and digital PCR [55][56] Question: Supply chain pressure points - Supply constraints are primarily related to electronic components, with expectations for improvement in Q2 [66][68] Question: Digital PCR growth outlook - Management remains confident in the growth potential of Droplet Digital PCR, anticipating strong double-digit growth [72] Question: Capital deployment and share buybacks - The company has $223 million available for potential share buybacks and remains opportunistic in capital deployment [76] Question: Demand outlook in China - The company views China as an underpenetrated market with significant growth opportunities, particularly in biopharma [82]

Title of Each ClassTrading Symbols Name of Each Exchange on Which Registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-792 ...

Financial Data and Key Metrics Changes - Net sales for Q3 2021 were $747 million, a 15.4% increase from $647.3 million in Q3 2020, with a currency-neutral growth of 13.8% [10] - Reported gross margin improved to 58.6% from 56.7% in Q3 2020, driven by settlement payments and productivity initiatives [14] - Reported net income for Q3 was $3.928 billion, with diluted earnings per share of $129.96, significantly influenced by changes in the valuation of equity securities [16] Business Line Data and Key Metrics Changes - Life Science Group sales increased to $373.5 million in Q3 2021 from $324 million in Q3 2020, a 15.3% increase on a reported basis [11] - Clinical Diagnostics Group sales rose to $372.2 million in Q3 2021 from $322.2 million in Q3 2020, marking a 15.5% increase on a reported basis [13] - Excluding COVID-related sales, the underlying Life Science business grew 4.1% on a currency-neutral basis [11] Market Data and Key Metrics Changes - Strong currency-neutral growth was observed in the Americas and Asia, while Europe experienced a slight decline due to tough year-over-year comparisons [11] - COVID-19-related sales were estimated at $57 million for the quarter, with expectations for a sequential decline in COVID-related demand in Q4 [11][8] Company Strategy and Development Direction - The company is focusing on addressing supply chain constraints and has implemented careful management to balance supply and demand [7] - The acquisition of Dropworks for approximately $125 million is expected to enhance Bio-Rad's entry into the lower-end segment of the digital PCR business [20] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued supply chain constraints into 2022, impacting customer delivery timing [22] - Full-year 2021 non-GAAP currency-neutral revenue growth is now guided to be between 12% and 13%, up from prior guidance [22] Other Important Information - The company introduced a mandatory vaccination requirement for all U.S. employees, reflecting its commitment to employee safety [8] - The effective tax rate for Q3 2021 was 21.8%, slightly lower than 21.9% in Q3 2020, influenced by unrealized gains in equity securities [16] Q&A Session Summary Question: Can you elaborate on the margin guidance in the fourth quarter? - Management clarified that operating margin guidance is slightly higher than previous quarters, with increased operating expenses expected [25][27] Question: What is the progress on restructuring initiatives announced in February? - Management reported that progress is on track, with most performance enhancements expected in 2023 [28] Question: Can you discuss supply and demand issues in more detail? - Management indicated that supply chain challenges are broad and affect various components, with expectations for these issues to persist into 2022 [30][31] Question: How is the diagnostics market in China performing? - Management noted that there has been no significant negative impact from centralized purchasing initiatives in China, and the company is monitoring the situation [38][39] Question: What is the growth outlook for the Life Science business? - Management expressed optimism about sustained double-digit growth in the Droplet Digital PCR portfolio, particularly in the biopharma market [34][42] Question: Can you provide insights on the Dropworks business? - Management refrained from providing detailed financials but emphasized that Dropworks is well-suited for cost-sensitive segments in the digital PCR market [49][50]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-138 ...